Monte Rosa Therapeutics Stock

Monte Rosa Therapeutics P/B

The P/B (Price-to-Book Ratio) of Monte Rosa Therapeutics (GLUE) as of Aug 6, 2026 is 5.86. In the previous year, P/B (Price-to-Book Ratio) was 6.13 — a change of -4.34% (lower).

P/B

5.86

YoY

-4.34%

Last updated:

P/B (Price-to-Book Ratio) of Monte Rosa Therapeutics is 2026 5.86 . P/B (Price-to-Book Ratio) of Monte Rosa Therapeutics was 2025 6.13 . It decreases by -4.34% lower compared to the previous year.
Access this data via the Eulerpool API

Monte Rosa Therapeutics Stock analysis

What does Monte Rosa Therapeutics do? Monte Rosa Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Monte Rosa Therapeutics stock

P/B (Price-to-Book Ratio) of Monte Rosa Therapeutics is 5.86 in 2026.

P/B (Price-to-Book Ratio) of Monte Rosa Therapeutics changed from 6.13 to 5.86, representing a -4.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Monte Rosa Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Monte Rosa Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Monte Rosa Therapeutics

All Key Metrics — Monte Rosa Therapeutics